Dopamine and Muscle Function in the Heat

NCT03515668 | Unknown

• 1 other identifier: 17-123
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

our goal is to study the effects of dopamine activity, using Ritalin ingestion, on neuromuscular function over the course of a progressive heating and cooling protocol developed in our lab. We hypothesize that Ritalin will minimize the previously reported progressive impairment in neuromuscular function with hyperthermia compared to placebo, suggesting that dopamine activity preserves neuromuscular capacity with hyperthermia.

Conditions

Muscle Force; Hyperthermia

Outcome Measures

Primary Outcomes (1)

• Wrist flexion torque

  Maximal voluntary contraction of wrist flexion

  2-4 hours after ingestion

Study Arms (2)

Ritalin

EXPERIMENTAL

20 mg Ritalin, 90 min before testing

Drug: Ritalin 20 mg Tablet

Control

PLACEBO COMPARATOR

Identical size/taste placebo pill, 90 min before testing

Drug: Placebo Oral Tablet

Interventions

Ritalin 20 mg Tablet DRUG

Single dose for all participants

Ritalin

Placebo Oral Tablet DRUG

Placebo with same appearance/taste

Control

Eligibility Criteria

• Age: 18 Years - 30 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• High aerobic fitness (\>55 mL/kg/min maximal aerobic capacity)

You may not qualify if:

• diagnosed cardiovascular, respiratory and/or neuromuscular disease, prescription of Ritalin or any drugs for hyperactivity within the past 1 year, any current prescription medication (except for asthma/allergy inhalers), any contraindications to Ritalin.

Sponsors & Collaborators

• Brock University: lead

Study Sites (1)

Brock University

St. Catharines, Ontario, L2S 3A1, Canada

Location

MeSH Terms

Conditions

Hyperthermia

Interventions

Methylphenidate; Tablets

Condition Hierarchy (Ancestors)

Body Temperature Changes; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Heat Stress Disorders; Wounds and Injuries

Intervention Hierarchy (Ancestors)

Phenylacetates; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals; Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Dosage Forms; Pharmaceutical Preparations

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Masking Details: Double-blinding of participant and investigator, with independent investigator in charge of placebo and drug.
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: Healthy males 18-30 years of age

Study Record Dates

• First Submitted: April 23, 2018
• First Posted: May 3, 2018
• Study Start: April 20, 2018
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2021
• Last Updated: February 10, 2021

Record last verified: 2021-02

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)